Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2107338 | Cancer Cell | 2012 | 11 Pages |
SummaryHow inflammation causes cancer is unclear. Interleukin-15 (IL-15) is a pro-inflammatory cytokine elevated in human large granular lymphocyte (LGL) leukemia. Mice overexpressing IL-15 develop LGL leukemia. Here, we show that prolonged in vitro exposure of wild-type (WT) LGL to IL-15 results in Myc-mediated upregulation of aurora kinases, centrosome aberrancies, and aneuploidy. Simultaneously, IL-15 represses miR-29b via induction of Myc/NF-κBp65/Hdac-1, resulting in Dnmt3b overexpression and DNA hypermethylation. All this is validated in human LGL leukemia. Adoptive transfer of WT LGL cultured with IL-15 led to malignant transformation in vivo. Drug targeting that reverses miR-29b repression cures otherwise fatal LGL leukemia. We show how excessive IL-15 initiates cancer and demonstrate effective drug targeting for potential therapy of human LGL leukemia.
► A single pro-inflammatory cytokine, IL-15, can initiate malignant transformation ► IL-15-mediated induction of Myc is central to the genesis of leukemia ► Targeting miR-29b with a single therapeutic induces long-term remission of leukemia